Filippa Stenberg
Director/Board Member at SWEDISH ORPHAN BIOVITRUM AB
Net worth: 13 599 $ as of 2024-04-29
Filippa Stenberg active positions
Companies | Position | Start | End |
---|---|---|---|
SWEDISH ORPHAN BIOVITRUM AB | Director/Board Member | - | - |
Independent Dir/Board Member | - | - | |
INVESTOR AB | Corporate Officer/Principal | - | - |
Investor AB (Investment Company)
Investor AB (Investment Company) Financial ConglomeratesFinance Investor AB (Investment Company) (Investor-IC) is the investment division of Investor AB (STO: INVE-B; LSE: INU), a Swedish public company established in 1916 as the investment vehicle for the Wallenberg family, which still owns a significant part of the firm. Investor AB is an industrial holding company which manages private equity funds listed on the Swedish stock exchange. Headquartered in Stockholm, Investor-IC is a socially responsible investor which supports the OECD Guidelines for Multinational Enterprises, including anti-corruption and human rights. They are committed to the development of society at large and sponsor youth, education and entrepreneurship activities. | Portfolio Manager-Equities | 2016-12-31 | - |
Analyst-Equity | 2011-12-31 | 2013-11-30 |
Career history of Filippa Stenberg
Former positions of Filippa Stenberg
Companies | Position | Start | End |
---|---|---|---|
Atlas Antibodies AB
Atlas Antibodies AB BiotechnologyHealth Technology Atlas Antibodies AB develops antibodies and reagents for Mass Spectrometry (MS)-based quantitative proteomics. Its project Human Protein Atlas aim to present an expression map of the complete human proteome. It offers characterized antibodies to various protein coding human genes; Triple A Polyclonals that are research grade rabbit polyclonal antibodies; and mouse monoclonal antibodies to selected proteins, as a complement to rabbit polyclonal antibodies. Its antibodies are used to study human proteins, for basic research purposes and clinical research in various disease areas, such as cancer and neurological brain diseases. The company was founded by Jan Fredrik Pontén, Karin Marianne Hansson, Henrik Wernérus, and Carl Erik Mathias Uhlén in 2006 and is headquartered in Stockholm, Sweden. | Corporate Officer/Principal | - | - |
Swedbank AB (Broker) | Sales & Marketing | 2011-08-21 | - |
Training of Filippa Stenberg
Stockholm School of Economics | Graduate Degree |
Statistics
International
Sweden | 7 |
Operational
Corporate Officer/Principal | 2 |
Sales & Marketing | 1 |
Analyst-Equity | 1 |
Sectoral
Finance | 4 |
Health Technology | 3 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
INVESTOR AB | Finance |
Private companies | 3 |
---|---|
Swedbank AB (Broker) | Finance |
Investor AB (Investment Company)
Investor AB (Investment Company) Financial ConglomeratesFinance Investor AB (Investment Company) (Investor-IC) is the investment division of Investor AB (STO: INVE-B; LSE: INU), a Swedish public company established in 1916 as the investment vehicle for the Wallenberg family, which still owns a significant part of the firm. Investor AB is an industrial holding company which manages private equity funds listed on the Swedish stock exchange. Headquartered in Stockholm, Investor-IC is a socially responsible investor which supports the OECD Guidelines for Multinational Enterprises, including anti-corruption and human rights. They are committed to the development of society at large and sponsor youth, education and entrepreneurship activities. | Finance |
Atlas Antibodies AB
Atlas Antibodies AB BiotechnologyHealth Technology Atlas Antibodies AB develops antibodies and reagents for Mass Spectrometry (MS)-based quantitative proteomics. Its project Human Protein Atlas aim to present an expression map of the complete human proteome. It offers characterized antibodies to various protein coding human genes; Triple A Polyclonals that are research grade rabbit polyclonal antibodies; and mouse monoclonal antibodies to selected proteins, as a complement to rabbit polyclonal antibodies. Its antibodies are used to study human proteins, for basic research purposes and clinical research in various disease areas, such as cancer and neurological brain diseases. The company was founded by Jan Fredrik Pontén, Karin Marianne Hansson, Henrik Wernérus, and Carl Erik Mathias Uhlén in 2006 and is headquartered in Stockholm, Sweden. | Health Technology |
- Stock Market
- Insiders
- Filippa Stenberg
- Experience